Cargando…
Repurposing of neprilysin inhibitor ‘sacubitrilat’ as an anti-cancer drug by modulating epigenetic and apoptotic regulators
Modifications in the epigenetic landscape have been considered a hallmark of cancer. Histone deacetylation is one of the crucial epigenetic modulations associated with the aggressive progression of various cancer subtypes. Herein, we have repurposed the neprilysin inhibitor sacubitrilat as a potent...
Autores principales: | Kumbhar, Navanath, Nimal, Snehal, Patil, Deeksha, Kaiser, V. Florian, Haupt, Joachim, Gacche, Rajesh N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279647/ https://www.ncbi.nlm.nih.gov/pubmed/37336927 http://dx.doi.org/10.1038/s41598-023-36872-0 |
Ejemplares similares
-
Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation
por: Kumbhar, Navanath, et al.
Publicado: (2022) -
Effects of BNP and Sacubitrilat/Valsartan on Atrial Functional Reserve and Arrhythmogenesis in Human Myocardium
por: Primessnig, Uwe, et al.
Publicado: (2022) -
Neprilysin Inhibitors and Bradykinin
por: Campbell, Duncan J.
Publicado: (2018) -
Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021) -
Epigenetic suppression of neprilysin regulates breast cancer invasion
por: Stephen, H M, et al.
Publicado: (2016)